In pulmonary arterial hypertension (PAH), blood vessels in the lungs are narrowed, blocked or destroyed. The damage slows blood flow through the lungs, and blood pressure in the lung arteries rises. The current clinical trial landscape for PAH and the challenges of clinical trial design for PAH are discussed in this touchRESPIRATORY interview with Dr Ioana Preston (Tufts University School of Medicine, Boston, MA, USA) as well as the limitations of clinical endpoints in previous studies.
The presentation titled ‘The Future of Clinical Trials in PH: Novel Trial Designs and Endpoints’ was presented at the Pulmonary Hypertension Association, June 10-12, 2022
Questions
- Could you give us a brief overview of the current clinical trial landscape for pulmonary arterial hypertension (PAH)?
- What are the challenges of clinical trial design for PAH?
- What have been the limitations of clinical endpoints in previous studies?
Disclosures: Ioana Preston discloses grant/research support from Acceleron, Janssen & United Therapeutics.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the PHA Hybrid Congress 2022.
